Skip to main content
Premium Trial:

Request an Annual Quote

Sekisui to Distribute Mesa Biotech Molecular POC Testing System

NEW YORK (GenomeWeb) – Sekisui Diagnostics and Mesa Biotech announced today a distribution deal for the Mesa Biotech point-of-care molecular system for flu A/B.

Mesa's POC flu test runs on a handheld molecular diagnostic device, consisting of a small controller dock and sample-to-answer testing cassettes. Clinicians wash patient nasal swabs in a buffer, add an aliquot to the cassette, place it in the dock, close the lid, and let the dock run the test. The cassette contains reagents for lysis, transcription of influenza virus RNA to DNA, and amplification.

Under the agreement, Sekisui will exclusively distribute Mesa's system in the US and Canada, pending clearance from regulators in both countries. Further details of the deal were not disclosed.

The system “offers the potential to strengthen our flu portfolio in the mid-to-long term by offering physicians the simplicity, convenience, and procedural familiarity of traditional POC rapid immunoassays, while providing the superior sensitivity, specificity, and information content of laboratory-based PCR testing," Sekisui Diagnostics President and COO Robert Schruender said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.